NASDAQ: INTS
Intensity Therapeutics Inc Stock Ownership - Who owns Intensity Therapeutics?

Insider buying vs selling

Have Intensity Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Joseph TalamoChief Financial Officer2025-06-3014,179$0.26
$3.70kBuy
John M. WesolowskiPrincipal Accounting Officer2025-06-3069,745$0.26
$18.20kBuy

1 of 1

INTS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when INTS insiders and whales buy or sell their stock.

INTS Shareholders

What type of owners hold Intensity Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Lewis H. Bender4.25%2,000,000$596.00kInsider
Sapient Capital LLC2.08%976,797$291.09kInstitution
Brown Advisory Inc0.28%130,072$38.76kInstitution
Mesirow Financial Investment Management Inc0.23%110,000$32.78kInstitution
John M. Wesolowski0.16%76,436$22.78kInsider
Geode Capital Management LLC0.15%72,813$21.70kInstitution
Sigma Planning Corp0.15%69,167$20.61kInstitution
Warberg Asset Management LLC0.15%68,400$20.38kInstitution
Vanguard Group Inc0.09%40,587$12.09kInstitution
Blair William Co0.08%37,805$11.27kInstitution

1 of 2

INTS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
INTS3.50%4.44%Net BuyingNet Buying
MRKR1.05%98.95%Net Buying
IMNN11.31%88.69%Net BuyingNet Buying
PRTG1.20%0.00%
CLDI8.72%91.28%Net Buying

Intensity Therapeutics Stock Ownership FAQ

Who owns Intensity Therapeutics?

Intensity Therapeutics (NASDAQ: INTS) is owned by 3.50% institutional shareholders, 4.44% Intensity Therapeutics insiders, and 92.06% retail investors. Lewis H. Bender is the largest individual Intensity Therapeutics shareholder, owning 2.00M shares representing 4.25% of the company. Lewis H. Bender's Intensity Therapeutics shares are currently valued at $596.00k.

If you're new to stock investing, here's how to buy Intensity Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.